Valuation: Vista Pharmaceuticals Limited

Market Cap 38Cr 39.61L 35.47L 32.63L 29.57L 55.26L 56.3L 3.89Cr 1.56Cr 20Cr 1.49Cr 1.45Cr 62Cr P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 44Cr 46.63L 41.77L 38.42L 34.81L 65.07L 66.29L 4.58Cr 1.84Cr 23Cr 1.75Cr 1.71Cr 73Cr EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
12/09 Vista Pharmaceuticals Limited Announces Resignation of Barkha Jain from Company Secretary and Compliance Officer, Effective September 4, 2026 CI
14/08 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
13/02 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
03/02 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
13/25/13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
16/25/16 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
30/25/30 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
19/25/19 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
12/25/12 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
13/24/13 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
13/24/13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
28/24/28 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
10/24/10 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
1 day-3.72%
1 week+6.34%
1 month-1.58%
3 months-6.33%
6 months-19.77%
Current year-23.71%
1 week 5.55
Extreme 5.55
6.5
1 month 5.32
Extreme 5.32
6.94
Current year 5.32
Extreme 5.32
8.87
1 year 5.32
Extreme 5.32
10.1
3 years 5.32
Extreme 5.32
19.32
5 years 5.32
Extreme 5.32
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 76 02/01/2014
Director/Board Member 87 16/06/1993
Director/Board Member 76 02/02/2010
Change 5-day change 1-year change 3-year change Capi.($)
-3.72%+6.34%-36.76%-57.47% 40.26L
+3.19%+11.31%+64.28%+155.91% 1,26300Cr
-0.73%+3.56%+44.65%+84.17% 66TCr
+1.41%+3.24%+35.25%+108.88% 52TCr
+0.42%+3.20%+55.81%+72.50% 39TCr
+2.18%+2.93%+73.90%+45.59% 37TCr
+1.12%+4.52%+34.76%+58.24% 31TCr
+6.96%+8.86%+11.95%+36.20% 29TCr
+1.15%+6.09%+56.15%+82.25% 25TCr
+3.06%+9.38%+42.48%+117.32% 21TCr
Average +1.50%+5.94%+38.25%+70.36% 42.62TCr
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2024 2025
Net sales 10Cr 10.83L 10L 9L 8L 15.12L 15.4L 1.06Cr 42.73L 5.41Cr 40.66L 39.8L 17Cr 10Cr 10.61L 10L 9L 8L 14.8L 15.08L 1.04Cr 41.84L 5.3Cr 39.82L 38.97L 17Cr
Net income -4.51Cr -5L -4L -4L -4L -7L -7L -46.68L -18.74L -2.37Cr -17.83L -17.45L -7.48Cr -4.65Cr -5L -4L -4L -4L -7L -7L -48.1L -19.31L -2.45Cr -18.37L -17.98L -7.71Cr
Net Debt 7.87Cr 8L 7L 7L 6L 11.57L 11.78L 81.43L 32.69L 4.14Cr 31.11L 30.45L 13Cr 6.67Cr 7L 6L 6L 5L 10L 10L 69.02L 27.71L 3.51Cr 26.37L 25.81L 11Cr
Projected Income Statement - Annual - Vista Pharmaceuticals Limited
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
30/26/30 ₹6.210 -3.72% 2,884
29/26/29 ₹6.450 +5.05% 22,495
28/26/28 ₹6.140 +4.07% 2,265
27/26/27 ₹5.900 +3.33% 318
26/26/26 ₹5.710 -2.23% 5,196
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock